Skip to main content

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

Publication ,  Journal Article
Mikhael, J; Belhadj-Merzoug, K; Hulin, C; Vincent, L; Moreau, P; Gasparetto, C; Pour, L; Spicka, I; Vij, R; Zonder, J; Atanackovic, D; Weng, Q ...
Published in: Blood cancer journal
May 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood cancer journal

DOI

EISSN

2044-5385

ISSN

2044-5385

Publication Date

May 2021

Volume

11

Issue

5

Start / End Page

89

Related Subject Headings

  • Treatment Outcome
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Resistance, Neoplasm
  • Antineoplastic Agents, Immunological
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mikhael, J., Belhadj-Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., … Leleu, X. (2021). A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer Journal, 11(5), 89. https://doi.org/10.1038/s41408-021-00478-4
Mikhael, Joseph, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.Blood Cancer Journal 11, no. 5 (May 2021): 89. https://doi.org/10.1038/s41408-021-00478-4.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood cancer journal. 2021 May;11(5):89.
Mikhael, Joseph, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.Blood Cancer Journal, vol. 11, no. 5, May 2021, p. 89. Epmc, doi:10.1038/s41408-021-00478-4.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood cancer journal. 2021 May;11(5):89.

Published In

Blood cancer journal

DOI

EISSN

2044-5385

ISSN

2044-5385

Publication Date

May 2021

Volume

11

Issue

5

Start / End Page

89

Related Subject Headings

  • Treatment Outcome
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Resistance, Neoplasm
  • Antineoplastic Agents, Immunological
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal